Thiogenesis Therapeutics Corp. Announces Final Acceptance from TSX Venture Exchange for Private Placement

Strategic Insights -

Thiogenesis Therapeutics Corp., a clinical-stage biopharmaceutical company, has received final acceptance from the TSX Venture Exchange for its heavily over-subscribed non-brokered private placement of 5,529,066 common shares at a price of C$0.75 per share, raising gross proceeds of C$4,146,800. The company plans to use the net proceeds for its Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) clinical trial expenses, creation and purchase of additional TTI-0102 for future clinical trials, and general working capital.

Key Takeaways:

  • Thiogenesis Therapeutics Corp. received final acceptance from the TSX Venture Exchange for its non-brokered private placement of 5,529,066 common shares at C$0.75 per share.
  • The private placement raised gross proceeds of C$4,146,800, with net proceeds expected to be used for MELAS clinical trial expenses, creation and purchase of additional TTI-0102, and general working capital.
  • Thiogenesis plans to proceed with clinical trials for its lead product candidate, TTI-0102, for Mitochondrial Encephalopathy Lactic Acidosis and Stroke (MELAS) and other indications.
  • The company has completed a Phase 2 clinical trial for MELAS and is awaiting results.
  • Thiogenesis' lead product candidate, TTI-0102, is an asymmetric disulfide and a prodrug that acts as a precursor to the thiol compound cysteamine.
  • Thiol compounds are versatile bio-active molecules involved in key biochemical reactions and metabolic processes, making them promising candidates to treat several diseases.

Statistics:

  • 5,529,066 common shares were sold at a price of C$0.75 per share, raising gross proceeds of C$4,146,800.
  • The net proceeds from the private placement will be used for MELAS clinical trial expenses, creation and purchase of additional TTI-0102, and general working capital.
  • The TSX Venture Exchange has approved the private placement, but the securities issued are subject to a 4-month plus one day hold period ending December 1, 2025.
  • Thiogenesis Therapeutics Corp. has completed a Phase 2 clinical trial for MELAS and is awaiting results for its lead product candidate, TTI-0102.

Sources:

  • Newsfile Corp. - August 14, 2025 - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news release of August 1, 2025, it has received final acceptance from the TSX Venture Exchange for its heavily over-subscribed non-brokered private placement (the "Offering") of 5,529,066 common shares (the "Offered Shares") in the capital of the Company for gross proceeds of C$4,146,800 at a price of C$0.75 per Offered Share.